-

Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET.

A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the company’s website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Contacts

For Investors:
Argot Partners
212.600.1902
gossamerbio@argotpartners.com

For Media:
Argot Partners
David Rosen
212.600.1902
david.rosen@argotpartners.com

Gossamer Bio, Inc.

NASDAQ:GOSS

Release Versions

Contacts

For Investors:
Argot Partners
212.600.1902
gossamerbio@argotpartners.com

For Media:
Argot Partners
David Rosen
212.600.1902
david.rosen@argotpartners.com

More News From Gossamer Bio, Inc.

Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2019 and provided a business update. “Our hearts are with the patients, families, caregivers and medical professionals suffering and sacrificing in the ongoing Cov...

Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria. Details for the ECCO presentations are a...

Gossamer Bio Announces Data Presentation at the 2020 Crohn’s & Colitis Congress

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple ascending dose study of GB004 in healthy volunteers have been accepted for presentation at the 2020 Crohn’s & Colitis Congress being held January 23- 25 in Austin, Texas. Details for th...
Back to Newsroom